{"id":6061,"date":"2009-12-30T11:25:37","date_gmt":"2009-12-30T10:25:37","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=6061"},"modified":"2013-08-05T05:38:18","modified_gmt":"2013-08-05T05:38:18","slug":"gsk-and-pfizer-launch-joint-hiv-collaboration","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/6061","title":{"rendered":"GSK and Pfizer launch joint HIV collaboration"},"content":{"rendered":"<p><strong>Following the initial announcement in April 2009 of a collaboration between GlaxoSmithKline and Pfizer\u0092s to create a new specialist company dedicated to HIV, called ViiV Healthcare was launched on 3 November 2009. GSK holds an 85% interest in ViiV Healthcare and Pfizer holds 15%.<\/strong><\/p>\n<p>ViiV Healthcare has 10 licensed medicines which generated \u00a31.6 billion in 2008 and a pipeline of seven investigative compounds, including five in phase II development and 10 other potential molecules to develop new HIV treatments.<\/p>\n<p>GSK previous Positive Action programme will be at the core of ViiV Healthcare\u0092s partnership programmes, supporting local communities impacted by HIV\/AIDS globally.<\/p>\n<p>The ViiV web site provides an overview of the new company and its current activities, including Positive Action and Community Partnerships, the R&amp;D pipeline, initiatives to improve access, and corporate governance:<\/p>\n<p>Source:<\/p>\n<p>Company Press Release: \u0093ViiV Healthcare &#8211; a global specialist HIV company established by GlaxoSmithKline and Pfizer to deliver advances in treatment and care for people living with HIV\u0094. (3 November 2009).<br \/>\n<a href=\"http:\/\/www.viivhealthcare.com\/\"> http:\/\/www.viivhealthcare.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Following the initial announcement in April 2009 of a collaboration between GlaxoSmithKline and Pfizer\u0092s to create a new specialist company dedicated to HIV, called ViiV Healthcare was launched on 3 November 2009. GSK holds an 85% interest in ViiV Healthcare &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-6061","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/6061","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=6061"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/6061\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=6061"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=6061"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=6061"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}